Breaking Biotech (@BreakingBioMatt) header
Breaking Biotech (@BreakingBioMatt) profile picture

Biotech investor/trader - Host of Breaking Biotech https://xitter.cf/t.co/P6wtEkED8z breakingbiomatt@gmail.com

San Diego, CA
Joined September 2017
Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)
Going to go live in the 1 o'clock hour PST. Talking about $ABVX, $SLS and $ERAS
6
718
Given the wording of the CRL, I wouldn't be surprised if an opportunistic lawyer gets interested
The PharmaBro @MartinShkreli got liquidated on his $CAPR short back in December (along with plenty of others who followed him). At the time he called the results fraudulent and said CEO Linda Marbán would end up in jail. Turns out he was right. $CAPR is down ~80% after hours after the FDA rejected the supplemental BLA with a strong CRL. The language specifically called out serious data integrity problems in a key trial - highly unusual and unusually pointed. @FDA has to set an example here. If I were @linda_marban , I’d be worried. Don’t bet against the pharma bro.
3
459
Going to go live in the 1 o'clock hour PST. Talking about $beam, $mrk and $rvmd
1
8
661
I'm starting a $RVMD position here
1
12
1,274
Going to go live in a couple hours, talking about $RYTM $RVMD and $MRNA
7
846
$TXG reporting basically flat YoY growth in Q3. Guiding 5% revenue growth 2026 over 2025, yet still trading at 12X multiple At least $TWST is guiding >20% rev growth
1
415
Nice to see another deal $RYTM! Feels like an expensive acquisition given the size of HO, but they must be confident about the potential in other MC4R-related obesity indications
1
2
829
Seems like an overreaction on a pretty positive ER $MDGL
4
819
After listening to the call, a couple of points stand out: - They refused to share details on early access customers/placements (fair to assume they haven't added anymore) - They haven't gotten buy-in from academics to submit S-10 grants (i.e. unlikely to have any academic instrument revenue until well into 2028) Seems like the company has big plans, but is still slow to execute with no sign that things are going to change. This should be trading below cash imo. Will see how the rest of the week plays out before considering more shorts.
1
222
$NAUT Q3 earnings: - $0.2M revenue (only 26K of that from services) - No ATM use in Q3 - Net loss: ~$16M - Cash $114M Will have to listen to the call to see if they have any more placements, but looks like another quarter without much adoption
3
4
1,641
Covering $NAUT, can't complain for a quick trade
1
8
1,971